Obesity Clinical Trials in Minneapolis, Minnesota

9 studies are recruiting for obesity in Minneapolis, Minnesota right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

   This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection frac…

   Stage

   Phase 3

   Ages

   18 to 99

   Site

   University of Minnesota, Minneapolis, Minnesota

   Locations

   686 in total

   Run by

   Amgen

   See if you can join NCT07037459 on ClinicalTrials.gov

2. A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

   This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM. Participants will be randomized to aleniglipron or placebo for a total of 76 weeks of treatmen…

   Stage

   Phase 3

   Ages

   18 to 79

   Site

   ACCOMPLISH-2 Research Site, Minneapolis, Minnesota

   Locations

   74 in total

   Run by

   Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

   See if you can join NCT07654374 on ClinicalTrials.gov

3. Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)

   The main purpose of this study, performed under Master Protocol J4M-MC-PWMP (NCT06672549), is to evaluate the efficacy, safety, and pharmacokinetics of tirzepatide as an addition to healthy lifestyle in participants 6 to less than 12 years of age, with obesity. Participation in the study will last …

   Stage

   Phase 3

   Ages

   6 to 11

   Site

   University of Minnesota Masonic Children's Hospital, Minneapolis, Minnesota

   Locations

   82 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07817875 on ClinicalTrials.gov

4. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

   The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants.

   Stage

   Phase 3

   Ages

   6 to 17

   Site

   University of Minnesota Masonic Children's Hospital, Minneapolis, Minnesota

   Locations

   116 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06672549 on ClinicalTrials.gov

5. A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

   This study will look at how well CagriSema and cagrilintide help children and adolescents with excess body weight lose weight. The study has 2 parts: main and extension study. In the main study, participants will either get CagriSema (a new study drug), cagrilintide (a new study drug), semaglutide …

   Stage

   Phase 3

   Ages

   8 to 18

   Site

   University of Minnesota, Minneapolis, Minnesota

   Locations

   121 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07253285 on ClinicalTrials.gov

6. AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

   The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the trea…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   International Diabetes Center, Minneapolis, Minnesota

   Locations

   74 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07533175 on ClinicalTrials.gov

7. A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

   This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive eit…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   International Diabetes Center, Minneapolis, Minnesota

   Locations

   303 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07564414 on ClinicalTrials.gov

8. Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

   This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the first month causes large gains in body fat in most people, even …

   Stage

   Phase 2

   Ages

   7 to 25

   Site

   Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota

   Locations

   16 in total

   Run by

   Etan Orgel

   See if you can join NCT05082519 on ClinicalTrials.gov

9. Project SHINE (Sleep Health INitiative for Equity): Culturally Informing a Sleep Extension Intervention for African American Adults

   The proposed research aims to reduce obesity-related health disparities by promoting healthy lifestyle behaviors among African Americans (AAs), given the high disease burdens associated with low physical activity, insufficient sleep, and obesity. There will be two phases to the proposed research. P…

   Stage

   Phase 1

   Ages

   21 to 75

   Site

   University of Minnesota, Minneapolis, Minnesota

   Run by

   University of Minnesota

   See if you can join NCT06226077 on ClinicalTrials.gov